Brief: Novartis Says Co to Acquire Morphosys AG For EUR 68 Per Share Or An Aggregate Of EUR 2.7Bn In Cash

Morphosys AG

05/02/2024 21:53

Feb 5 (Reuters) - Novartis Ag  NOVN.S :
    * NOVARTIS TO STRENGTHEN ONCOLOGY PIPELINE WITH AGREEMENT TO
ACQUIRE MORPHOSYS AG FOR EUR 68 PER SHARE OR AN AGGREGATE OF EUR
2.7BN IN CASH
    * PELABRESIB RECENTLY MET ITS PRIMARY ENDPOINT OF SPLEEN
VOLUME
REDUCTION AND DEMONSTRATED FAVORABLE TRENDS IN SYMPTOM
IMPROVEMEN
    * NOVARTIS - FIRST LINE OF TREATMENT IN MYELOFIBROSIS WITH
REGULATORY FILING WITH U.S. FDA PLANNED FOR H2 2024
    * UNTIL TRANSACTION CLOSES, MORPHOSYS AG WILL CONTINUE TO
OPERATE
AS A SEPARATE, INDEPENDENT COMPANY
    * NOVARTIS - NOVARTIS WILL OWN PELABRESIB WITH A
WELL-TOLERATED
SAFETY PROFILE PROVIDED IN COMBINATION WITH RUXOLITINIB FOR
PATIENTS WITH MYELOFIBROSIS
    * PELABRESIB AND RUXOLITINIB COMBINATION REGULATORY FILING
WITH
U.S. FDA PLANNED FOR H2 2024
    * TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARD OF
DIRECTORS
OF BOTH COMPANIES,

Source text for Eikon:  ID:nGNE69X5c4 
Further company coverage:  NOVN.S 

 ((Reuters.Briefs@thomsonreuters.com;))